Patents by Inventor Walter Laird

Walter Laird has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mutant diphtheria toxin conjugates
    Patent number: 5792458
    Abstract: A potent and specific immunotoxin is prepared by coupling an inactivated diphtheria toxin to a binding moiety such as a monoclonal antibody or transferrin. The immunotoxins are specific for human tumors and leukemias and are indistinguishable in cell toxicity from that of the native toxin linked to the binding domain without the toxicity to other cells. The immunotoxin is useful in treating graft versus host disease as well as selectively killing tumor cells, such as medulloblastoma and glioblastoma cells.
    Type: Grant
    Filed: October 17, 1994
    Date of Patent: August 11, 1998
    Assignees: The United States of America as represented by the Department of Health and Human Services, Cetus Corporation
    Inventors: Virginia G. Johnson, Larry Greenfield, Richard J. Youle, Walter Laird
  • Method of preparing diphtheria immunotoxins
    Patent number: 5208021
    Abstract: A potent and specific immunotoxin is prepared by coupling an inactivated diphteria toxin to a binding moiety such as a monoclonal antibody or transferrin. The immunotoxins are specific for human tumors and leukemias and are indistinguishable in cell toxicity from that of the native toxin linked to the binding domain without the toxicity to other cells. The immunotoxin is useful in treating graft versus host disease as well as selectively killing tumor cells, such as medulloblastoma and glioblastoma cells.
    Type: Grant
    Filed: January 25, 1989
    Date of Patent: May 4, 1993
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Cetus Corporation
    Inventors: Virginia G. Johnson, Larry Greenfield, Richard J. Youle, Walter Laird
  • Monoclonal anti-human breast cancer antibodies
    Patent number: 5169774
    Abstract: Murine monoclonal antibodies, or fragments thereof, that bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described.
    Type: Grant
    Filed: May 6, 1988
    Date of Patent: December 8, 1992
    Assignee: Cetus Oncology Corporation
    Inventors: Arthur E. Frankel, David B. Ring, Walter Laird